

Figure 1A

Table 1. Baseline demographics and clinical characteristics

Demographic/characteristic	History of NP (n = 165)			No history of NP (n = 894)
	All (n = 165)*	NP ≤ 2 years before randomization (n = 83)	NP > 2 years before randomization (n = 82)	
Age, mean (SD), years	52.3 (12.3)	51 (13.2)	53.6 (11.3)	48.9 (16.6)
Female, n (%)	91 (55.2)	42 (50.6)	49 (59.8)	581 (65.0)
BMI, mean (SD), kg/m ²	28.0 (5.8)	27.5 (5.7)	28.6 (5.9)	28.6 (7.2)
ICS dose group, n (%) ^b				
Medium	37 (22.4)	19 (22.9)	18 (22.0)	226 (25.3)
High	128 (77.6)	64 (77.1)	64 (78.0)	667 (74.6)
Maintenance OCS use, n (%)	22 (13.3)	8 (10.8)	13 (15.9)	78 (8.7)
Prebronchodilator FEV ₁ , mean (SD), L	1.9 (0.7)	2 (0.7)	1.8 (0.7)	1.8 (0.7)
Exacerbations in the past 12 months, n (%)				
≤ 2	84 (50.9)	37 (44.6)	47 (57.3)	551 (61.6)
> 2	81 (49.1)	46 (55.4)	35 (42.7)	343 (38.4)
FeNO level, ppb				
Mean (SD)	54.1 (47.4)	62.4 (55.8)	45.7 (35.5)	41.9 (39.2)
Median (min, max)	42.0 (5.0, 265.0)	48.0 (5.0, 265.0)	36.0 (5.0, 210.0)	28.0 (5.0, 235.0)
Blood eosinophil count, cells/μL				
Mean (SD)	517.9 (744.6)	619.3 (980.7)	415.4 (358.0)	307.3 (289.4)
Median (min, max)	360.0 (0.0, 8170.0)	450.0 (0.0, 8170.0)	305.0 (20.0, 2030.0)	240.0 (0.0, 4640.0)
Serum total IgE, IU/mL				
Mean (SD)	492.4 (984.0)	507.3 (1140.6)	477.4 (801.8)	578.4 (1079.5)
Median (min, max)	160.8 (1.5, 7406.3)	158.2 (13.8, 7406.3)	173.7 (1.5, 4357.4)	204.8 (1.5, 12 823.2)
FEIA-positive for any perennial aeroallergen, n (%) ^c	75 (45.5)	38 (45.8)	37 (45.1)	605 (67.7)

*Of the 165 patients with a history of NP, SNOT-22 scores were available for 131 patients at baseline.

^bMedium-dose ICS: fluticasone propionate 500 μg/day or equivalent; high-dose ICS: fluticasone propionate > 500 μg/day or equivalent; there was one patient from the placebo group without a history of NP who received fluticasone propionate < 500 μg/day or equivalent.


^cPositive for ≥ 1 perennial aeroallergen (cat dander, dog dander, cockroach, dust mite [*Dermatophagoides farinae*, *D. pteronyssinus*] and mold mix).

BMI, body mass index; FEIA, fluorescence enzyme immunoassay; FeNO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroids; Ig, immunoglobulin; NP, nasal polyps; OCS, oral corticosteroids; Q4W, every 4 weeks; SD, standard deviation; SNOT, Sino-Nasal Outcomes Test.

Figure 1B

Characteristic	History of NP		No history of NP	
	Placebo (n = 75)	Tezepelumab 210 mg Q4W (n = 90)	Placebo (n = 458)	Tezepelumab 210 mg Q4W (n = 438)
Age, years, mean (SD)	52.0 (12.4)	52.6 (12.4)	48.5 (16.4)	49.4 (16.9)
Female, n (%)	39 (52.0)	52 (57.8)	298 (65.4)	283 (64.6)
BMI, kg/m ² , mean (SD)	27.2 (4.8)	28.7 (6.4)	28.5 (7.2)	28.7 (7.2)
ICS dose level, ^a n (%)				
Medium	16 (21.3)	21 (23.3)	116 (25.4)	110 (25.1)
High	59 (78.7)	69 (76.7)	339 (74.3)	328 (74.9)
Maintenance OCS use, n (%)	10 (13.3)	12 (13.3)	41 (9.0)	37 (8.4)
Pre-bronchodilator FEV ₁ , L, mean (SD)	1.8 (0.7)	1.9 (0.7)	1.9 (0.7)	1.8 (0.7)
Pre-bronchodilator FEV ₁ , % PN, mean (SD)	59.5 (16.4)	63.2 (16.2)	63.3 (18.2)	62.7 (18.3)
Exacerbations in the past 12 months, n (%)				
< 2	38 (50.7)	46 (51.1)	287 (62.9)	264 (60.3)
> 2	37 (49.3)	44 (48.9)	169 (37.1)	174 (39.7)
FeNO level, ppb, median (min, max)	45.0 (5.0, 265.0)	41.0 (5.0, 213.0)	28.0 (5.0, 231.0)	29.0 (5.0, 235.0)
Blood eosinophil count, cells/ μ L, median (min, max)	400.0 (0.0, 8170.0)	340.0 (20.0, 3650.0)	240.0 (0.0, 4640.0)	240.0 (0.0, 1390.0)
Serum total IgE, IU/mL, median (min, max)	146.0 (8.5, 7406.3)	174.4 (1.5, 4357.4)	207.8 (1.5, 9740.9)	198.9 (1.5, 12 823.2)
FEIA positive for any perennial aeroallergen, ^b n (%)	32 (42.7)	43 (47.8)	309 (67.8)	296 (67.6)
SNOT-22 scores	(n = 62)	(n = 69)	(n = 26)	(n = 24)
Total score, mean (SD) [range 0–110]	49.3 (19.6)	49.6 (20.1)	36.2 (20.1)	32.5 (21.3)
Domain scores, mean (SD) [range 0–5]				
Ear/facial	1.4 (1.0)	1.5 (1.1)	1.0 (0.9)	1.0 (1.2)
Emotion	1.8 (1.3)	1.8 (1.2)	1.3 (1.0)	1.3 (1.4)
Function	2.5 (1.2)	2.3 (1.2)	1.8 (1.1)	1.8 (1.3)
Nasal	2.6 (0.8)	2.7 (1.0)	2.0 (1.0)	1.5 (1.0)
Sleep	2.5 (1.2)	2.4 (1.1)	1.9 (1.3)	1.8 (1.3)

Figure 2. LS mean change from baseline to week 52 in SNOT-22 score in patients with a history of NP











Figure 4




















Figure 6A





Figure 6C





Figure 6D






Figure 7

SEQ ID NO	Description	Sequence
1	TSLP nucleotide seq	gcagccagaaaagctctggagcatcaggagagactccaaacttaaggccaacagcatgggtgaataaagggttcctgtgactggcaatgagaggaacacctggcttgagcactggccctaaaggcgccttacagatcctctacactcgtgggtgggaagagtttagtgaaactgggtggaattgggtgtccacgtatgttcccttttgccttactatagttctgtcagttctttcaggaaaatcttcattctacaacttgagggtggtgttaacttacgacttcaactaactgtgactttggaagattaaagcagcctatctcagtagctatttctaaagacctgattacatatatgagtgggacaaaagtaccgagttcaacaacacctctctttagcaaatcgccacattgccttactgaaatccagagcctaaccttcaatccaccgccggctgcgcgtcgctcgccaaaagaatgttcgccaataaggctgccttagctatctggtgccagggtatttcggaaactcagataaaatgctactcaggcaatgaagaagaggaagaaaagtgcacaacccaataaagtgtctggaacaagtgtcacaaattacaaggatttgggcgtgcgttcaatcgaccttactgaaacaacacagtaaacacctctttattatggtcataatttcacagcccaaaaataaatcatctttattaaagtaaaaaaaa
2	TSLP amino acid seq	MFPFALLYVLSVSRKIFILQLVGLVLTDFINCDFEKIKAAYLSTISKDLITYMSGTKSTEFNNTVSCSNRPHCLTEIQSLTFNPITAGCASLAKEMFAMKTKAALAIWCPGYSETQINATQAMKKRRKRKVITNKCLEQVSQLQLGLWRRFNRPLLKKQ
3	Light chain CDR1	GGNNLGSKSVH
4	Light chain CDR2	DDSDRPS
5	Light chain CDR3	QVWDSSSDHVV
6	Heavy chain CDR1	TYGMH
7	Heavy chain CDR2	VIWYDGSNKHYSVKG
8	Heavy chain CDR3	APQWELVHEAFDI
9	VH nucleotide	cagatgcagctgggtggagctctgggggagggcgtggtccagcctcgggaggtccctgagactctcctgtgcagcgtctggtattcaccttcagaaacctatggcatgcactgggtccgcagggtccaggcaaggagctggagtgggtggcagttatatggtatgatggaagtataaaacactatgcagactccgtgaaggccgattccaccatcaccagagacaattccaagaacacctctgaatctgcaaatgaaacagcctgagagccgagcacacggctgtgtattactgtgcgagagccctcagtgaggagtagttcatgaagcttttgatatctggggccaaagggacaatggtcacccgtctcttcaGGNNLGKSVHDDSDRPSQVWDSSSDHVVTYGMHVIWYDGSNKHYSVKGAPQWELVHEAFDIQMQLVESGGGVVQPGRSLRLSCAASGFTFRITYGMHWVRQAPGKGLEWAVIWDGGSNKHYSVKGRTTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS
10	VH amino acid	
11	VL nucleotide	tcctatgtgctgactcagccacctcgtgtcagtggtggccccccaggcacagacggccaggtattacctgtgggggaaaaaacaccttggaagtaaaagtgtgcactggtaccagcagaagccaggccagggccccctgtgctggtcgtctatgatg

12	VL amino acid	atagcgaccggccctcatggatccctgagcgattctctggctccaaactctgggaacacggccaccctgaccatc agcaggggcgaagccgggatgagccgactattactgtcaggtgtgggatagtagtcatgtggtatt tcggcgaggaggaagctgaccgtccta SYVLTQPPSVSVAPGQTARITCGGNILGSKSVHWYQQKPGQAPVLVYDDSDRPSWIPERFSGNSGNTAII SRGEAGDEADYYCQVWDSSTDHVVFGGTKLTVL QMQLVESGGG VQPGGRSLRL SCAASGFTFR TYGMHWVRQA PGKGLEWVAV IWYDGSNKH ADSVKGRFTI TRDNSKNTLN LQMNSLRAED TAVYCARAP QWELVHEAFD IWQGQTMVTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPTV VSWNSGALIS GVHTFPAVLQ SSGLYSLSV VIVPSSNFGT QTYTCNVDHK PSNTKVDKIV ERKCCVECPP CPAPPVAGPS VFLEPPKPKD TLMISRTPEV TCVVVDVSHD DPEVQFNWYV DGVEVHNAKT KPREEQFNST FRVSVLTIV HQDWLNGKEY KCKVSNKGLP APIEKTISKI KGQPREPQVY TLPPTSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPPMLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK SYVLTQPPSV SVAPGQTARI TCGGNILGSK SVHWYQQKPG QAPVLVYDD SDRPSWIPER FSGNSGNTA TLTISRGEAG DEADYYCQVW DSSSDHVVFG GGTCLTVLQK PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW KADSSPVKAG VETITPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE GSIVEKIVAP TECS
13	Full length heavy chain, CDRs underlined	
14	Full length light chain, CDRs underlined	

Figure 7 continued